Key Neuroblastoma Drugs Market Players:
- CELLECTAR BIOSCIENCES, INC.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- APEIRON Biologics AG
- Pfizer Inc.
- Eli Lilly and Company
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- MacroGenics Inc.
- Marsala Biotech Inc.
- Johnson & Johnson Services, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of neuroblastoma drugs is estimated at USD 885.33 million.
The global neuroblastoma drugs market size crossed USD 836.4 million in 2025 and is likely to register a CAGR of over 6.5%, exceeding USD 1.57 billion revenue by 2035.
North America neuroblastoma drugs market is projected to command a 36% revenue share by 2035, attributable to rising incidence rates and expanding approval of technologically advanced and orphan-designated therapies.
Key players in the market include Bayer AG, Merck & Company, Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac, Perrigo Company plc, Vetoquinol SA, Zoetis Inc., Ceva, Nutreco N.V..
